|
End-of-day quote
Taiwan S.E.
21/08/2026
|
5-day change | 1st Jan Change | ||
| 1,400.00 TWD | +1.82% |
|
-6.67% | +230.42% |
| 08-17 | PharmaEssentia Corp Submits Post-approval Applications to Taiwan Regulator to Expand Besremi Use | MT |
| 08-13 | PharmaEssentia Clarifies Report Projecting 2026 Revenue | MT |
Company Valuation: PharmaEssentia Corporation
Data adjusted to current consolidation scope
| Fiscal Period: December | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|---|---|---|
| Market Cap 1 | 78,065 | 143,840 | 114,578 | 204,725 | 173,829 | 580,204 | - | - |
| Change | - | 84.26% | -20.34% | 78.68% | -15.09% | 233.78% | - | - |
| Enterprise Value (EV) 1 | 75,148 | 133,629 | 94,995 | 183,725 | 153,423 | 553,680 | 545,477 | 580,204 |
| Change | - | 77.82% | -28.91% | 93.4% | -16.49% | 260.89% | -1.48% | 6.37% |
| P/E | -27.1x | -98.6x | -179x | 69.3x | 34.6x | 52.9x | 34.5x | - |
| PBR | 19.1x | 11.2x | 4.79x | 7.45x | 5.46x | 13.5x | 10.5x | - |
| PEG | - | 1.8x | 3x | -0x | 0.5x | 0x | 0.6x | - |
| Capitalization / Revenue | 119x | 49.9x | 22.4x | 21x | 11.1x | 20.5x | 15x | 16.3x |
| EV / Revenue | 114x | 46.4x | 18.6x | 18.9x | 9.81x | 19.6x | 14.1x | 16.3x |
| EV / EBITDA | -29x | -74.2x | -57.8x | 87.3x | 28.8x | 39.6x | 29.6x | 35x |
| EV / EBIT | -26.6x | -65.9x | -49.6x | 106x | 31.1x | 43.1x | 30.1x | 35.7x |
| EV / FCF | -29.7x | -73.5x | -49.8x | 102x | 41.7x | 103x | 51.5x | - |
| FCF Yield | -3.37% | -1.36% | -2.01% | 0.98% | 2.4% | 0.97% | 1.94% | - |
| Dividend per Share 2 | - | - | - | 0.8936 | 1.352 | 4 | 2.35 | - |
| Rate of return | - | - | - | 0.18% | 0.32% | 0.29% | 0.17% | - |
| EPS 2 | -8.773 | -3.932 | -1.568 | 7.214 | 12.25 | 26.46 | 40.55 | - |
| Distribution rate | - | - | - | 12.4% | 11% | 15.1% | 5.79% | - |
| Net sales 1 | 656.5 | 2,882 | 5,106 | 9,735 | 15,635 | 28,278 | 38,607 | 35,594 |
| EBITDA 1 | -2,595 | -1,800 | -1,645 | 2,104 | 5,327 | 13,965 | 18,433 | 16,591 |
| EBIT 1 | -2,822 | -2,028 | -1,913 | 1,736 | 4,928 | 12,836 | 18,117 | 16,243 |
| Net income 1 | -2,811 | -1,375 | -623.8 | 2,966 | 5,045 | 11,053 | 17,033 | - |
| Net Debt 1 | -2,917 | -10,211 | -19,582 | -21,000 | -20,406 | -26,524 | -34,728 | - |
| Reference price 2 | 238.02 | 387.49 | 281.07 | 499.59 | 423.70 | 1,400.00 | 1,400.00 | 1,400.00 |
| Nbr of stocks (in thousands) | 327,980 | 371,210 | 407,644 | 409,783 | 410,264 | 414,432 | - | - |
| Announcement Date | 02/03/22 | 01/03/23 | 27/02/24 | 26/02/25 | 03/03/26 | - | - | - |
1TWD in Million2TWD
Estimates
P/E, Detailed evolution
| P/E (Y) | EV / Sales (Y) | EV / EBITDA (Y) | Dividend Yield (Y) | Capi.($) | ||
|---|---|---|---|---|---|---|
 | 52.91x | 19.58x | 39.65x | 0.29% | 18.22B | |
| 21.45x | 7.54x | 15.37x | 1.38% | 72.12B | |
| 37.53x | 9.72x | 29.82x | 0.04% | 65.85B | |
| -18.08x | 7.59x | -9.85x | -.--% | 29.28B | |
| -79.5x | 14.86x | -71.64x | -.--% | 27.47B | |
| 33.76x | 6.66x | 17.64x | -.--% | 26.7B | |
| 27.2x | 5.1x | 17.12x | -.--% | 20.06B | |
| 2460.33x | 41.28x | -5047.29x | -.--% | 16.4B | |
| 16.73x | 4.96x | 11.58x | -.--% | 13.4B | |
| -24.56x | 24.8x | -27.62x | -.--% | 12.3B | |
| Average | 252.78x | 14.21x | -502.52x | 0.17% | 30.18B | |
| Weighted average by Cap. | 145.77x | 11.60x | -267.13x | 0.35% |
Y-o-Y evolution of P/E
Historical PBR trend
Evolution Enterprise Value / Sales
Change in Enterprise Value/EBITDA
Year-on-year evolution of the Yield
- Stock Market
- Stocks
- 6446 Stock
- Valuation PharmaEssentia Corporation
Select your edition
All financial news and data tailored to specific country editions
